THOMAS JAMES DOYLE - 02 Jan 2026 Form 4 Insider Report for Kura Oncology, Inc. (KURA)

Role: SVP, Finance & Accounting
Signature: Teresa Bair, Attorney-in-fact for Thomas Doyle
Issuer symbol: KURA
Transactions as of: 02 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 06 Jan 2026, 16:30:15 UTC
Previous filing: 14 Nov 2025
Next filing: 27 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
DOYLE THOMAS JAMES	SVP, Finance & Accounting	C/O KURA ONCOLOGY, INC., 4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO	Teresa Bair, Attorney-in-fact for Thomas Doyle	06 Jan 2026	0001910331

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KURA	Common Stock	Award	$0	+21,250	+16%	$0.000000	152,309	02 Jan 2026	Direct	F1, F2
holding	KURA	Common Stock						500	02 Jan 2026	spouse's 401(k)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KURA	Option to purchase common stock	Award	$0	+42,500		$0.000000	42,500	02 Jan 2026	Common Stock	42,500	$10.34	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/27, 1/26/28, 1/26/29 and 1/26/30.
F2	Includes 802 shares acquired on November 17, 2025 pursuant to the Issuer's Employee Stock Purchase Plan.
F3	This option vests in 48 equal monthly installments commencing on the grant date.